Table 3 shows that no significant overall survival, ipsilateral breast or regional relapse-free survival differences were found for this high-risk cohort at 5 years as compared to low risk patients. There were also no significant differences for ipsilateral breast, axillary or regional (ipsilateral breast or axillary) recurrences in the infiltrating lobular, age ≤50, HER2/neu positive or tumor size ≥2 cm between cohorts. Here, ERBB2 is linked to neoplasm.